LAVAS Study
Start date:Historic End date:
June 2014 Co-ordinated by:
NHS Lothian
Lactate, Arterial and Venous Agreement in Sepsis – LAVAS trial
Aim
To determine whether an agreement between peripheral venous and arterial lactate exists in patients presenting to an Emergency Department with sepsis.
Trial Design
A prospective observational study in a consecutive sample of eligible and consented patients in the Royal Infirmary of Edinburgh
Eligibility criteria (summary)
Patients who present to the Emergency Department with suspected sepsis
Chief Investigator
Dr Deepankar Datta
Specialist Trainee Emergency Medicine
Local PI
Dr Deepankar Datta
Specialist Trainee Emergency Medicine
Research Team
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
KRAKIL Study
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.